PT  - JOURNAL ARTICLE
AU  - Theofilas, Panos
AU  - Piergies, Antonia M.H.
AU  - Li, Song Hua
AU  - Petersen, Cathrine
AU  - Ehrenberg, Alexander J.
AU  - Eser, Rana A.
AU  - Chin, Brian
AU  - Yang, Teddy
AU  - Khan, Shireen
AU  - Ng, Raymond
AU  - Spina, Salvatore
AU  - Seeley, Willian W.
AU  - Miller, Bruce L.
AU  - Arkin, Michelle R.
AU  - Grinberg, Lea T.
TI  - Caspase-6-cleaved tau is relevant in Alzheimer’s disease but not in other tauopathies: diagnostic and therapeutic implications
AID  - 10.1101/2021.01.28.21250322
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.28.21250322
4099  - http://medrxiv.org/content/early/2021/05/20/2021.01.28.21250322.short
4100  - http://medrxiv.org/content/early/2021/05/20/2021.01.28.21250322.full
AB  - Aim Tau truncation (tr-tau) by active caspase-6 (aCasp-6) generates toxic tau fragments prone to self-aggregation. Yet, the relationship between aCasp-6, different forms of tr-tau, and hyperphosphorylated tau (p-tau) accumulation in human brains with Alzheimer’s disease (AD) and other tauopathies remains unclear.Methods We generated two neoepitope monoclonal antibodies against tr-tau sites (D402 and D13) targeted by aCasp-6. Then, we used 5-plex immunofluorescence to quantify the neuronal and astroglial burden of aCasp-6, tr-tau, p-tau, and their co-occurrence in healthy controls, AD, and primary tauopathies.Results Casp-6 activation was strongest in AD, followed by Pick’s disease (PiD), but almost absent in 4-repeat (4R) tauopathies. In neurons, the tr-tau burden was much more abundant in AD than in 4R tauopathies, and disproportionally higher when normalizing by p-tau pathology. Tr-tau astrogliopathy was detected in low numbers in 4R tauopathies. Unexpectedly, about half of tr-tau positive neurons in AD lacked p-tau aggregates.Conclusions Early modulation of aCasp-6 to reduce tr-tau pathology is a promising therapeutic strategy for AD, and possibly PiD, but is unlikely to benefit 4R tauopathies. The large percentage of tr-tau-positive neurons lacking p-tau suggests that not all neurons that are vulnerable to tau pathology are detected by a conventional p-tau Ser 202 antibody and that AD has distinct mechanisms of tangle formation. Therapeutic strategies against tr-tau pathology could be necessary to modulate tau abnormalities in AD. The disproportionally higher burden of tr-tau in AD supports the investigation of biofluid biomarkers against N-terminus tr-tau, which could detect AD and differentiate it from 4R tauopathies at a single patient level.3 - sentence summary Tau truncation (tr-tau) by active caspase-6 (aCasp-6) generates toxic tau fragments prone to self-aggregation, but the relationship between aCasp-6, tr-tau, and hyperphosphorylated tau (p-tau) accumulation in Alzheimer’s disease (AD) and other tauopathies remains unclear. We generated two neoepitope monoclonal antibodies against tr-tau sites (D402 and D13) targeted by aCasp-6 and used 5-plex immunofluorescence to quantify the neuronal and astroglial burden of aCasp-6, tr-tau, p-tau, and their co-occurrence in brains from healthy controls, AD, and primary tauopathies. We detected relatively high Casp-6 activation in AD, followed by Pick’s disease (PiD). aCasp-6 was almost absent in 4-repeat (4R) tauopathies, suggesting that early modulation of aCasp-6 to reduce tr-tau pathology is a promising therapeutic strategy in AD, and possibly PiD, but is unlikely to benefit 4R tauopathies.Competing Interest StatementM.R.A. is cofounder of Elgia Therapeutics, which is developing caspase-6 inhibitors for inflammatory diseases. The other authors have declared no conflict of interest.Funding StatementThis study was supported by the National Institutes of Health K01AG053433 (P.T), K24AG053435, R56AG057528 and U54 NS100717 (L.T.G), K08AG052648 (S.S), P30AG062422 and P01AG019724 (B.L.M), UCSF RAP Pilot Award program (P.T), UCSF RAP Team Science Grant (L.T.G., M.R.A.), Alzheimer's Association AARG-16-441514 (L.T.G., M.R.A.), Rainwater Charitable Foundation (M.R.A.), and a Catalyst award from ShangPharma Innovation (M.R.A., T.Y., S.K, R.N.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of human brain tissue has received ethical approval by the University of California San Francisco Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.3R3-repeat4R4-repeataCasp-6Active caspase-6ADAlzheimer’s diseaseAGDArgyrophilic grain diseaseCBDCorticobasal degenerationIFImmunofluorescenceITGInferior temporal gyrusMFGMiddle frontal gyrusmAbMonoclonal antibodyNFTNeurofibrillary tanglep-tauHyperphosphorylated tauPHFPaired helical filamentsPiDPick’s diseasePSPProgressive supranuclear palsyPTMPost-translational modificationstr-tauTruncated tauTMATissue microarrays